lunes, 23 de junio de 2025

Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs Drugmaker alleges Hims has been engaging in ‘deceptive marketing’ of GLP-1 treatments

https://www.statnews.com/2025/06/23/novo-nordisk-ends-deal-with-hims-due-compounding-concerns-obesity-drugs-glp1/

No hay comentarios:

Publicar un comentario